Comprehensive characterisation of cancer predisposition genes using the Hereditary Cancer Panel
)
- Published on: January 20 2026
)
Overview
Hereditary cancers are caused by an inherited mutation and account for ~5-10% of diagnosed cancers. Accurate detection of these mutations is critical for appropriate treatment and cascade family testing.
The Hereditary Cancer Panel from Oxford Nanopore Technologies resolves 258 full-length genes implicated in hereditary cancer predisposition, including introns and promoters. Streamline your precision oncology assays with this scalable, accessible, and cost-effective method.
In this workflow, you will:
- Find out how the Hereditary Cancer Panel enhances cancer research
- Discover our best practice sequencing workflow in detail, starting from the recommended extraction and library preparation, through to analysis with EPI2ME
- Learn about our recommended sequencing kit and devices
